Evidence map›Paper›PMID 31558626›Full record

Observational studyThorax2019

Evaluation of cardiovascular risk in a lung cancer screening cohort.

Mamta Ruparel, Samantha L Quaife, Jennifer L Dickson, Carolyn Horst, Stephen Burke, Magali Taylor, Asia Ahmed, Penny Shaw, May-Jan Soo, Arjun Nair and 11 more

Registry-linked trialOpen access · hybridFull text readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Thorax, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02558101 (Randomised Controlled Trial to Test Novel Invitation Methods and Materials Targeted to Increase Informed Uptake of Lung Cancer Screening in Individuals at High Risk of Lung Cancer), which is not on this map. Cited by 49 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 1 pooled it
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02558101 nacompletednot on this map

Randomised Controlled Trial to Test Novel Invitation Methods and Materials Targeted to Increase Informed Uptake of Lung Cancer Screening in Individuals at High Risk of Lung Cancer

TypeinterventionalSponsorUniversity College, LondonRan2015 to 2022Enrolled1,997ConditionsLung CancerArmsControl invitation materials, Intervention invitation materials
3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 9 institutions in 5 countries.

Mamta RuparelLungs for Living Research Centre, UCL Respiratory, University College London, London, UK.ORCID 0000-0001-8880-6567
Samantha L QuaifeResearch Department of Behavioural Science and Health, University College London, London, UK.
Jennifer L DicksonLungs for Living Research Centre, UCL Respiratory, University College London, London, UK.
Carolyn HorstLungs for Living Research Centre, UCL Respiratory, University College London, London, UK.
Stephen BurkeDepartment of Radiology, Homerton University Hospital NHS Foundation Trust, London, UK.
Magali TaylorDepartment of Radiology, University College London Hospitals NHS Foundation Trust, London, UK.
Asia AhmedDepartment of Radiology, University College London Hospitals NHS Foundation Trust, London, UK.
Penny ShawDepartment of Radiology, University College London Hospitals NHS Foundation Trust, London, UK.
May-Jan SooDepartment of Radiology, Homerton University Hospital NHS Foundation Trust, London, UK.
Arjun NairDepartment of Radiology, University College London Hospitals NHS Foundation Trust, London, UK.
Anand DevarajDepartment of Radiology, Royal Brompton Hospital, London, UK.
Emma Louise O'DowdRespiratory Medicine Unit, David Evans Research Centre, Nottingham University Hospitals NHS Trust, Nottingham, UK.ORCID 0000-0001-6904-1327
Angshu BhowmikRespiratory Medicine, Homerton University Hospital NHS Foundation Trust, London, UK.
Neal NavaniLungs for Living Research Centre, UCL Respiratory, University College London, London, UK.
Karen SennettKillick Street Health Centre, London, UK.
Stephen W DuffyWolfson Institute of Preventive Medicine, Barts and London, London, UK.
David R BaldwinRespiratory Medicine Unit, David Evans Research Centre, Nottingham University Hospitals NHS Trust, Nottingham, UK.
Reecha SofatInstitute of Cardiovascular Science, University College London, London, UK.
Riyaz S PatelInstitute of Cardiovascular Science, University College London, London, UK.
Aroon HingoraniInstitute of Cardiovascular Science, University College London, London, UK.
Sam M JanesLungs for Living Research Centre, UCL Respiratory, University College London, London, UK s.janes@ucl.ac.uk.ORCID 0000-0002-6634-5939
University College London Hospitals NHS Foundation Trust · GBCardiovascular Institute Hospital · JPHomerton University Hospital NHS Foundation Trust · GBUniversity College London · GBNottingham University Hospitals NHS Trust · GBRoyal Brompton Hospital · GBThe Behaviouralist (United Kingdom) · GBThe London College · GBWolfson Medical Center · IL

Funding

British Heart Foundation FS/14/76/30933Cancer Research UK 17976Cancer Research UK 24460Cancer Research UK C50664/A24460Department of HealthWellcome TrustWellcome Trust WT107963AIA
6 · The paper itself

Abstract

introductionLung cancer screening (LCS) by low-dose computed tomography (LDCT) offers an opportunity to impact both lung cancer and coronary heart disease mortality through detection of coronary artery calcification (CAC). Here, we explore the value of CAC and cardiovascular disease (CVD) risk assessment in LCS participants in the Lung Screen Uptake Trial (LSUT).

methodsIn this cross-sectional study, current and ex-smokers aged 60-75 were invited to a 'lung health check'. Data collection included a CVD risk assessment enabling estimation of 10 year CVD risk using the QRISK2 score. Participants meeting the required lung cancer risk underwent an ungated, non-contrast LDCT. Descriptive data, bivariate associations and a multivariate analysis of predictors of statin use are presented.

resultsOf 1005 individuals enrolled, 680 were included in the final analysis. 421 (61.9%) had CAC present and in 49 (7.2%), this was heavy. 668 (98%) of participants had a QRISK2≥10% and QRISK2 was positively associated with increasing CAC grade (OR 4.29 (CI 0.93 to 19.88) for QRISK2=10%-20% and 12.29 (CI 2.68 to 56.1) for QRISK2≥20% respectively). Of those who qualified for statin primary prevention (QRISK2≥10%), 56.8% did not report a history of statin use. In the multivariate analysis statin use was associated with age, body mass index and history of hypertension and diabetes.

conclusionsLCS offers an important opportunity for instituting CVD risk assessment in all LCS participants irrespective of the presence of LDCT-detected CAC. Further studies are needed to determine whether CAC could enhance uptake and adherence to primary preventative strategies.

Indexed as

AgedCardiovascular DiseasesCohort StudiesCoronary DiseaseCross-Sectional StudiesDrug UtilizationEarly Detection of CancerFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLung NeoplasmsMaleMass ScreeningMiddle AgedPrimary PreventionProspective StudiesHydroxymethylglutaryl-CoA Reductase InhibitorsLung Cancer

Identifiers

PMID31558626
PMCPMC6902068
OpenAlexW2975145552

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.